Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential

• Published in: Expert review of anti-infective therapy Vol. 21; no. 3; p. 235
• Main Authors: Russo, Andrew T, Grosenbach, Douglas W, Honeychurch, Kady M, Long, Paul G, Hruby, Dennis E
• Format: Journal Article
• Language: English
• Published: England 04-03-2023
• Subjects: Benzamides - pharmacology; Child; Disease Outbreaks - prevention & control; Humans; Isoindoles; Mpox (monkeypox); Smallpox - drug therapy; Smallpox - prevention & control; tecovirimat; TPOXX; antiviral; intravenous formulation; smallpox; monkeypox virus; biodefense; ST-246; mpox
• ISSN: 1744-8336
• DOI: 10.1080/14787210.2023.2170350

Tecovirimat oral capsule formulation is approved in the US and Canada for treatment of smallpox and in the United Kingdom (UK) and European Union (EU) for treatment of multiple human orthopoxvirus diseases, including mpox. Smallpox is considered a serious threat, and there is currently an unprecedented global mpox outbreak.
A brief summary of the threat of smallpox, the threat of increasing mpox spread in endemic regions, and the unprecedented emergence of mpox into non-endemic regions is presented. The tecovirimat intravenous formulation clinical development program leading to USFDA approval for smallpox treatment is discussed.
As of January 2023 tecovirimat is approved to treat mpox in the UK and EU. However, published clinical trial data evaluating tecovirimat efficacy and safety in mpox patients is pending. Increasing global prevalence of mpox highlights the potential benefits of a well-characterized, effective, and safe antiviral treatment for mpox infection. Ongoing trials in mpox patients may provide results supporting the use of tecovirimat to treat this disease. USFDA approval of tecovirimat for post-exposure prophylaxis in the event of a smallpox release, and the development of pediatric liquid formulations for patients under 13 kg, could provide additional public health benefits.